Zobrazeno 1 - 9
of 9
pro vyhledávání: '"FU-QUN WU"'
Autor:
Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Li-Yuan Ma, Da-Peng Liu, Ying Liu, Ting-Ting Feng, Fan-Yi Meng, Xiao-Li Liu, Qian-Li Jiang, Xiao-Qin Chen, Jing-Lei Liu, Ping Liu, Zhu Chen, Sai-Juan Chen, Guang-Biao Zhou
Publikováno v:
PLoS ONE, Vol 4, Iss 7, p e6257 (2009)
BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CM
Externí odkaz:
https://doaj.org/article/635934ee35264748a8f9bac393fc239e
Autor:
Xiaodong Li, Jieyu Ye, Jian‑Sheng Zhong, Qing‑Xiu Zhong, Rui Cao, Chang Xin Yin, Wei‑Wei Chen, Fu Qun Wu, Zhixiang Wang, Xue Jie Jiang, Fanyi Meng, Dan Xu, Li‑Bing Liao
Publikováno v:
Experimental and Therapeutic Medicine. 11:2061-2065
Low concentrations of imatinib (IM) in bone marrow cells have been linked with poor prognosis in patients with chronic myeloid leukemia (CML), which may be caused by the emergence of ATP-binding cassette transporter B1 (ABCB1) mutations. The aim of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fb9bc9b987a2e82a190cbac0e3b4621
https://doi.org/10.3892/etm.2016.3127
https://doi.org/10.3892/etm.2016.3127
Publikováno v:
Carcinogenesis. 35:905-914
Celastrol binds CIP2A and enhances CIP2A-CHIP interaction, leading to ubiquitination/degradation of CIP2A and inhibition of lung cancer cells in vitro and in vivo. Celastrol potentiates cisplatin's efficacy by suppressing the CIP2A-Akt pathway, and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e01088162e3366960a8383a9ac3f3554
https://doi.org/10.1093/carcin/bgt395
https://doi.org/10.1093/carcin/bgt395
Autor:
Xue-Jie, Jiang, Fan-Yi, Meng, Hong-Sheng, Zhou, Qiang, Wang, Fu-Qun, Wu, Kai-Kai, Huang, Ming, Huang, Zhi-Xiang, Wang, Wei-Wei, Chen
Publikováno v:
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 32(8)
To investigate reversal effect of histone deacetylase inhibitor LBH589 alone or in combination with proteasome inhibitor bortezomib on drug resistance in acute myeloid leukemia (AML) and its mechanism.Ex vivo cultures of HL-60/ADM cells and fresh ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::922573434e343e29f844f55a950f6129
https://pubmed.ncbi.nlm.nih.gov/22338177
https://pubmed.ncbi.nlm.nih.gov/22338177
Autor:
Dan Xu, Rong Lin, Hongsheng Zhou, Li Bin Liao, Chang Xin Yin, Han He, Rui Cao, Kai Kai Huang, Fanyi Meng, Fu Qun Wu, Zhong Xin Zheng, Zheng Shan Yi, Mo Yang, Xue Jie Jiang, Qiang Wang
Publikováno v:
International journal of oncology. 40(2)
Anaphase promoting complex cofactor Cdh1 plays a critical role in tumor suppression and genomic stability in cancer. However, its role in chronic myeloid leukemia (CML) remains unclear. We treated both wild-type and imatinib-resistant K562 cells with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88bf1a155016a608e91c1268b1986356
https://pubmed.ncbi.nlm.nih.gov/22002244
https://pubmed.ncbi.nlm.nih.gov/22002244
Autor:
CHANG-XIN YIN, WEI-WEI CHEN, QING-XIU ZHONG, XUE-JIE JIANG, ZHI-XIANG WANG, XIAO-DONG LI, JIE-YU YE, RUI CAO, LI-BING LIAO, FU-QUN WU, DAN XU, JIAN-SHENG ZHONG, FAN-YI MENG
Publikováno v:
Experimental & Therapeutic Medicine; May2016, Vol. 11 Issue 5, p2061-2065, 5p
Publikováno v:
Blood. 122:3635-3635
Tanshinone IIA (TIIA) isolated from Danshen (Radix Salviae Miltiorrhiza Bge) is a derivative of phenanthrenequinone, which has been used for centuries to treat hypercoagulation related diseases. Our previous study showed that TIIA has neural protecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b179fed2c5e46d514c14bd3e3e5a5d11
https://doi.org/10.1182/blood.v122.21.3635.3635
https://doi.org/10.1182/blood.v122.21.3635.3635
Autor:
Guang-Biao Zhou, Fu-Qun Wu, Liyuan Ma, Qianli Jiang, Ting-Ting Feng, Ping Liu, Xiaoqin Chen, Xiao-Fen Pan, Zhu Chen, Zheng Hu, Ying Liu, Xiaoli Liu, Jing-Lei Liu, Sai Juan Chen, Fanyi Meng, Dapeng Liu
Publikováno v:
PLoS ONE
PLoS ONE, Vol 4, Iss 7, p e6257 (2009)
PLoS ONE, Vol 4, Iss 7, p e6257 (2009)
BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92cc58c9c75b0afc2681c81c43d48808
https://doi.org/10.1371/journal.pone.0006257
https://doi.org/10.1371/journal.pone.0006257
Autor:
Fu-Qun Wu, Zheng Hu, Dapeng Liu, Sai-Juan Chen, Xiaoli Liu, Juan Li, Feng-Xiang Zhang, Guang-Biao Zhou, Xiaofeng Li, Jiang Zhu
Publikováno v:
Blood. 108:4771-4771
STI571/Gleevec/imatinib, a rationally-designed agent that occupies the ATP-binding site of BCR-ABL and stabilizes the protein in its closed, inactive conformation, has been a remarkable success for the treatment of chronic myeloid leukemia (CML). How
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5d73b63e55fd46a2eb4395c141e10a9
https://doi.org/10.1182/blood.v108.11.4771.4771
https://doi.org/10.1182/blood.v108.11.4771.4771